Research Journal of Pharmaceutical Dosage Forms and Technology
  • Year: 2021
  • Volume: 13
  • Issue: 4

Nose to Brain Drug Delivery System

  • Author:
  • Gayatri D Patil*, Aditya R Nikam, Paresh A. Patil, Aakash D. Sonar
  • Total Page Count: 6
  • Published Online: Jun 29, 2022
  • Page Number: 335 to 340

Ahinsa Institute of Pharmacy, Dondaicha425408.

*Corresponding Author E-mail: drjigarvyas@gmail.com

Online Published on 29 June, 2022.

Abstract

The treatment of brain disorders is particularly challenging due to the presence of a variety of formidable obstacles to deliver drugs selectively and effectively to the brain. Blood-brain-barrier (BBB) constitutes the major obstacle to the uptake of drugs into the brain following systemic administration. An intranasal delivery provides some drugs with short channels to bypass the blood-brain barrier (BBB), especially for those with fairly low brain concentrations after a routine delivery, thus greatly enhancing the therapeutic effect on brain diseases. The nasal mucosa is nearby the brain, cerebrospinal fluid (CSF) and the drug concentrations can exceed plasma concentrations. a longer retention time at the nasal mucosal surface, penetration enhancement of the active through the nasal epithelia, and a reduction in drug metabolism in the nasal cavity. Indications where nose-to- brain products are likely to emerge first include the following: neurodegeneration, post-traumatic stress disorder, pain, and glioblastoma.

Keywords

Central nervous system (CNS), Blood-brain barrier (BBB), Cerebrospinal fluid, (CSF) Nasal cavity